HLA typing market seen reaching $1.78 billion by 2035

The global HLA typing market is projected to grow from $0.91 billion in 2026 to $1.78 billion by 2035, driven by more transplant procedures, wider use of next-generation sequencing, and precision medicine adoption. Market Research Future says reimbursement changes, cloud bioinformatics and cell therapy demand are also expanding the market beyond transplant care.

Why it matters: - HLA typing is becoming more central to transplant care, drug safety and cell therapy development. - The market’s growth reflects broader adoption of precision medicine and higher demand for exact donor-recipient matching. - More activity in organ transplantation also increases the number of tests needed across compatibility checks and follow-up monitoring.

What happened: - Market Research Future projects the global HLA typing market will rise from $0.91 billion in 2026 to $1.78 billion by 2035. - The forecast implies a 7.65% compound annual growth rate from 2026 through 2035. - The market base was estimated at $0.85 billion in 2025. - The company points to record organ-transplant volumes, next-generation sequencing and precision medicine mainstreaming as major growth drivers.

The details: - The U.S. recorded more than 48,000 organ transplants in 2024, creating demand for donor-recipient compatibility testing. - CMS launched the Medicare IOTA Model in January 2025, linking hospital payments to transplant outcomes and indirectly rewarding precise tissue-matching diagnostics. - The U.S. National Marrow Donor Program has standardized high-resolution typing for unrelated donor searches. - Molecular assays held 54.9% of technology demand in 2025, making them the leading HLA typing technology segment. - Reagents and consumables held about 68.5% of product and service revenue in 2025. - Software and services are the fastest-growing segment, with a projected 9.15% CAGR from 2026 to 2035. - Diagnostic applications held about 68% of the market in 2025. - Commercial service providers accounted for about 43.5% of end-user share in 2025. - North America held about 41.8% of the market in 2025. - Europe ranked second with 27.2% share in 2025. - Asia-Pacific is the fastest-growing region, with a projected 9.45% CAGR through 2035. - The report also tracks market positions and recent product moves from Thermo Fisher Scientific, Illumina, QIAGEN, CareDx, Omixon and GenDx.

Between the lines: - The market is shifting away from serological and low-resolution methods toward sequencing-based testing that can resolve alleles more clearly. - Cloud bioinformatics is becoming a bigger part of the value chain because interpretation and allele calling can now be delivered as recurring software and service revenue. - Precision medicine is widening HLA typing use beyond transplantation into pharmacogenomics, autoimmune risk assessment and oncology-related applications. - Cell therapy developers also need HLA-characterized donor pools, which could pull the market deeper into therapeutics manufacturing.

What’s next: - The report expects AI-driven allele interpretation systems to influence more than 60% of HLA typing workflows in leading countries by 2030. - Decentralized testing models using portable sequencing are expected to broaden access by 2028. - Software and services are projected to grow faster than reagent sales through 2035. - HLA-typed biobanks may become more valuable as off-the-shelf cell therapy programs expand.

The bottom line: - HLA typing is moving from a transplant support tool to a broader precision-medicine infrastructure market, with sequencing, software and recurring services driving the next phase of growth.